Astaxanthin
Astaxanthin scored 7.1 / 10 (💪 Strong recommend) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient. Astaxanthin is a red-orange xanthophyll carotenoid, primarily sourced from the freshwater microalga Haematococcus pluvialis .
What It Is
Astaxanthin is a red-orange xanthophyll carotenoid, primarily sourced from the freshwater microalga Haematococcus pluvialis . Its terminal hydroxyl and keto groups let it span the full width of a cell membrane, quenching free radicals simultaneously at the water-lipid interface and deep inside the lipid bilayer. It crosses the blood-brain and blood-retinal barriers and accumulates in hippocampus, cortex, and retinal pigment epithelium, giving it reach no other common carotenoid has.
Upside (3.46 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.3 | 0.825 | |
| Breadth of Benefits | 15% | 4.5 | 0.675 | |
| Evidence Quality | 25% | 3.4 | 0.850 | |
| Speed of Onset | 10% | 3.2 | 0.320 | |
| Durability | 10% | 2.3 | 0.230 | |
| Bioindividuality Upside | 15% | 3.7 | 0.555 | |
| Total | 3.455 |
Upside Rationale
Efficacy (3.3/5.0). Effect sizes are meaningful but rarely transformative. The strongest signals are on biomarkers rather than hard clinical endpoints: MDA (lipid peroxidation) drops SMD −0.95 in the Rahimi 2022 meta-analysis of 12 RCTs, TAC rises SMD +1.10 in Hashemi 2024's exercise meta-analysis of 9 RCTs, skin elasticity improves SMD +0.77 in Zhou 2021's meta of 8 RCTs, and HDL rises SMD +0.42 with triglycerides falling SMD −0.31 in Laurindo 2025's lipid meta. Clinical endpoints are smaller: diastolic BP drops only 2.77 mmHg in hypertensive patients, HbA1c moves 0.05–0.07 percentage points in mixed data, and wrinkle depth changes are not significant. Cycling time-trial improvements (Earnest 2011: −121 s at 20 km, 4 mg/day) and endurance fat oxidation (Brown 2021, 12 mg/day) are the rare clear behavioral effects. Overall this sits in the "meaningful benefit" Cohen's d 0.3–0.8 band.
Breadth of benefits (4.5/5.0). This is astaxanthin's strongest dimension. The membrane-spanning antioxidant mechanism translates into signal across skin (photoprotection, elasticity, moisture), eye (asthenopia, computer vision syndrome, AMD when stacked with lutein), exercise (endurance, fat oxidation, DOMS, TAC), cardiovascular (HDL, TG, DBP in patients, fibrinogen), cognition (reaction time, processing speed, working memory in older populations), oxidative stress (MDA, SOD, IL-6 in T2DM), metabolic (Matsuda insulin sensitivity index improved 8.29 → 11.45 in Urakaze 2021), and female ART outcomes (PCOS, endometriosis, poor ovarian responders). Few supplements touch this many systems with real human RCT data.
Evidence quality (3.4/5.0). The base is impressive in volume: Satoh 2019 pooled 87 human trials, there are at least 5 published meta-analyses (Zhou 2021 skin, Hashemi 2024 exercise, Laurindo 2025 lipids, Choi 2022 BP, Rahimi 2022 oxidative stress), and bioavailability and pharmacokinetics are well-characterized (Odeberg 2003, Okada 2009). But quality is uneven. Most trials are small (n < 100), short (≤ 12 weeks), single-center, and Asian-population dominant. Laurindo 2025 explicitly rates CV evidence as "low to very low certainty" under GRADE. No dedicated Cochrane systematic review exists, which is notable for a supplement with 25+ years on market. Key claims like male fertility benefit (Comhaire 2005, pregnancy rate 54.5% vs 10.5%) failed replication (Kumalic 2021, n=72, null). Industry funding from AstaReal, Fuji, Cyanotech, and BGG is heavy. A −0.3 integrity adjustment is applied for funding concentration. The 2025 Frontiers in Medicine skin meta-analysis concluded evidence is still "insufficient for routine clinical recommendation" for photoaging.
Speed of onset (3.2/5.0). Plasma steady state is reached around day 10 at 8 mg/day. Oxidative stress markers (MDA, SOD) shift within 3 weeks (Park 2010). Eye fatigue improves in 2–4 weeks (Nagaki 2002, Hongo 2023). Skin endpoints take 4–16 weeks. Cognitive improvements take 8–12 weeks and are modest. Exercise performance gains appear after 2–4 weeks of loading. Faster than most polyphenols but slower than stimulants or sleep interventions.
Durability (2.3/5.0). Effects fade when supplementation stops. Erythrocyte half-life is ~28 hours, plasma ~15–21 hours, and tissue stores clear over weeks. Ito 2018's UV photoprotection result showed some persistence at follow-up, but this is the exception. Astaxanthin is a chronic-use intervention, not a durable one-and-done like resistance training or fasted adaptation.
Bioindividuality upside (3.7/5.0). The membrane antioxidant mechanism is universal, so most adults should see at least the oxidative stress effects at proper dosing. But response depends heavily on context: smoking cuts bioavailability roughly in half; fat co-ingestion is required (3–5× absorption vs fasted); Hongo 2023 found the acuity benefit only in subjects ≥40 years (not <40); Hayashi 2018's cognitive signal was only in the <55 subgroup; responders to the lipid and metabolic effects skew toward already dysmetabolic populations. The best responders are older adults, screen-heavy workers, athletes on high oxidative loads, women with ART/PCOS concerns, and anyone with baseline high MDA/low antioxidant status.
Downside (2.00 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.0 | 0.600 | |
| Side Effect Profile | 15% | 1.5 | 0.225 | |
| Financial Cost | 5% | 1.8 | 0.090 | |
| Time/Effort Burden | 5% | 1.0 | 0.050 | |
| Opportunity Cost | 5% | 1.2 | 0.060 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.425 | |||
| × 1.4 (risk asymmetry) | 1.995 |
Downside Rationale
Safety risk (2.0/5.0). One of the cleaner safety profiles in the supplement space, with real caveats. Satoh 2019's review of 87 human studies (including 35 at ≥12 mg/day up to 40 mg/day for 90 days) reported zero serious adverse events. No deaths, no hospitalizations, no organ failure from astaxanthin monotherapy. FDA FAERS/CAERS shows no signal. EFSA has set an ADI of 14 mg/day for a 70 kg adult and the 2020 Novel Food opinion approved 8 mg/day supplements for adults and adolescents 14+. The single documented serious adverse event is Santiyanon and Yeephu 2019's warfarin interaction case (INR jumped 1.4 → 10.38 within 48 hours at 8 mg/day, fully reversed with vitamin K). This is a pharmacodynamic interaction, not intrinsic toxicity; the BioHarmony catastrophic floor targets intrinsic risks and does not fire for co-medication-mediated AEs. EU restricts supplemental use to ≥14 years because dietary fish intake already has infants exceeding the ADI by 524%. Long-term data above 20 mg/day beyond 12 weeks does not exist: this is the largest gap in the profile.
Side effect profile (1.5/5.0). All mild, all reversible. Across RCTs: GI upset (bloating, loose stool) in 1–3% of participants, usually when taken on an empty stomach; occasional red/orange stool color at high doses; mild headache 1–2% (usually in cognition trials); carotenoderma (yellow-orange palm/sole tint) above ~12 mg/day after 3–4 weeks, purely cosmetic and clearing within 2–3 weeks of discontinuation; a meta-analytic ALT elevation of about +1.92 U/L that is statistical but not clinically significant; mild DBP lowering of 1–3 mmHg. Reddit and Examine user reports match: "mild, safe, maybe underwhelming at low dose."
Financial cost (1.8/5.0). Quality natural astaxanthin (BioAstin, AstaReal, Nutrex Hawaii, Algatech AstaPure) runs roughly $15–30 per month at 12 mg/day. This is affordable enough to sit in most supplement stacks without displacing priorities. The cheaper retail channel is a false economy (see Scenarios below).
Time/effort burden (1.0/5.0). One capsule with any meal containing fat. There is no protocol to learn, no injection, no prep. Zero friction.
Opportunity cost (1.2/5.0). Astaxanthin complements nearly everything: other antioxidants, omega-3, creatine, polyphenols, sleep and training protocols. It does not crowd out other interventions or demand behavioral bandwidth.
Dependency/withdrawal (1.0/5.0). No known dependency or withdrawal mechanism. You can stop at any time with no rebound.
Reversibility (1.0/5.0). Fully reversible. Tissue levels clear over weeks after discontinuation. No permanent physiological changes.
Verdict
✅ Best for: Adults 40+ looking for a broad-spectrum antioxidant with real human RCT data; heavy screen users with eye fatigue; endurance athletes wanting TAC and fat-oxidation support; people with low baseline antioxidant status or visible photoaging; women going through ART for PCOS, endometriosis, or poor ovarian response; prediabetic and dyslipidemic individuals wanting modest lipid and insulin-sensitivity improvements without drug side effects.
❌ Avoid if: On warfarin, DOACs, or dual antiplatelet therapy; pregnant, lactating, or under 14 (regulatory-restricted in EU); planning surgery in the next 2 weeks; expecting a finasteride-level DHT drop (the 98% 5α-reductase inhibition claim is from in-vitro and combination products, not from isolated astaxanthin in humans); intolerant of fatty meals (bioavailability collapses without fat); shopping the Amazon/Walmart retail channel without brand due diligence (63% of 2023 samples failed NOW Foods' potency testing).
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Impact | New Tier |
|---|---|---|
| 12-month RCT at ≥20 mg/day confirms no signal | Safety → 1.5, Durability → 3.0 | 7.5 / 💪 Strong recommend |
| Independent Cochrane review confirms skin/eye/CV meta-findings | Evidence → 4.2 | 7.4 / 💪 Strong recommend |
| Large independent RCT shows d > 0.5 clinical cognitive benefit | Efficacy → 4.0, Breadth → 4.8 | 7.8 / 💪 Strong recommend |
| User sources from Amazon/Walmart (63% fail potency) | De facto efficacy → 1.5 | 5.4 / ⚖️ Neutral |
| Additional serious warfarin interaction cases surface | Safety → 3.0 | 6.7 / 👍 Worth trying |
| New lipid meta-analysis upgrades GRADE certainty to moderate | Evidence → 3.8 | 7.3 / 💪 Strong recommend |
| Person is on warfarin, DOAC, or antiplatelet therapy | Safety → 4.0 (individual) | 6.3 / 👍 Worth trying |
Key Evidence Sources
- Zhou X et al. 2021. Nutrients . Skin effects meta-analysis, 11 studies, 8 RCTs pooled.
- Hashemi B et al. 2024. Complementary Therapies in Medicine . Exercise performance meta-analysis, 9 RCTs, TAC SMD +1.10.
- Laurindo LF et al. 2025. Nutrients . Lipid profile meta-analysis, 8 RCTs. HDL SMD +0.42, TG SMD −0.31.
- Choi HD et al. 2022. Complementary Therapies in Medicine . Blood pressure meta-analysis, 10 RCTs, n=493.
- Rahimi B et al. 2022. Nutrition Research . Oxidative stress meta-analysis, 12 RCTs. MDA SMD −0.95.
- Brendler T and Williamson EM. 2019. Phytotherapy Research . Safety review of 87 human trials.
- Grimmig B et al. 2024. Cognitive function and neurodegenerationncritical review.
- Tominaga K et al. 2017. 65 subjects, 6 or 12 mg × 16 weeks.
- Ciaraldi TP et al. 2023. Diabetes, Obesity and Metabolism . Prediabetic dyslipidemic adults, 12 mg × 24 weeks.
- Urakaze M et al. 2021. Nutrients . 12 mg × 12 weeks, n=44. Matsuda index 8.29 → 11.45.
- Hongo N et al. 2023. 9 mg × 6 weeks, n=59 VDT workers, ≥40 agensubgroup only.
- Talens-Estarelles C et al. 2025. Advances in Therapy . 64nchildren 10–14, 4 mg × 84 days, CVS-Q improved.
- Earnest CP et al. 2011. 4 mg × 28 days, 21 cyclists, 20 km TT.
- Brown DR et al. 2021. 12 mg × 7 days, 40 km TT. Whole-body fatnoxidation.
- Fakhri M et al. 2023. Endometriosis ART patients, 12 mg × 12 weeks.
- Gharaei R et al. 2023. PCOS ART patients, ER stress markers.
- Kumalic SI et al. 2021. Male infertility, 16 mg × 3 months. Nullnreplication.
- EFSA 2020 Novel Food Opinion. EFSA Journal 2020;18(2):5993.
- Santiyanon W and Yeephu S. 2019. Warfarin interaction case report. J Clin Pharm Ther .
- FDA GRN 580.
- NOW Foods 2023 astaxanthin retail testing. 14 of 22 samples failednpotency.
- Odeberg JM et al. 2003. Pharmacokinetics.
- Brendler T et al. 2022. Natural vs synthetic.
- Galasso C et al. 2018. Neuroprotection review.
Other interventions for Cardiovascular
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits. Every downside dimension is multiplied by 1.4 before subtraction because harm potential is more consequential than benefit potential — the precautionary principle encoded as math.
Upside: 3.455 / 5.00
Downside (post-1.4×): 1.995 / 5.00
EV = 1.460
Score = ((EV + 7) / 12) × 10 = 7.1 / 10
